Cutting-Edge Developments in utilizing Lipid Nano-carrier for Enhanced Drug Delivery
DOI:
https://doi.org/10.37285/ijpsn.2024.17.5.8Abstract
Nanocarriers have emerged as promising drug delivery systems due to their unique properties and capabilities. This abstract provides an overview of the concept of nanocarriers as drug delivery systems, highlighting their significance and potential applications. The report begins by introducing the background and significance of drug delivery systems. It emphasizes the limitations of conventional drug delivery methods and the need for more efficient and targeted approaches. Nanocarriers offer a solution to these challenges by providing controlled and targeted drug delivery, leading to improved therapeutic outcomes. The advantages and challenges of nanocarriers as drug delivery systems are discussed. The advantages include enhanced drug stability, prolonged drug release, improved bioavailability, and targeted delivery to specific tissues or cells. However, challenges such as manufacturing complexity, regulatory considerations, and potential toxicity need to be addressed for successful clinical translation. The report then highlights the different types of nanocarriers used in drug delivery, including lipid-based nanocarriers, polymeric nanocarriers, and inorganic nanocarriers. Each type is briefly described, along with their synthesis methods, properties, and applications. The report also covers the principles of drug delivery using nanocarriers, focusing on the mechanisms of drug loading and release from nanocarriers. It discusses the factors influencing drug release kinetics and the strategies employed for enhanced drug delivery, such as targeting strategies. Finally, the report concludes by emphasizing the importance of nanocarriers in various therapeutic applications, including cancer drug delivery, central nervous system drug delivery, gene delivery, vaccines, and treatment of infectious diseases. It also highlights the future perspectives and challenges in the field of nanocarrier-based drug delivery systems.
Downloads
Keywords:
Nanocarriers, Drug delivery system, Factors influencing drug release kinetics, Controlled release, Nano Technology, Targeted drug delivery system, Nanocarriers, Drug delivery system, Factors influencing drug release kinetics, Controlled release, Nano Technology, Targeted drug delivery system
Published
How to Cite
Issue
Section
References
Nair AB, Shah J, Al-Dhubiab BE, Jacob S, Patel SS, Venugopala KN, Morsy MA, Gupta S, Attimarad M, Sreeharsha N, Shinu P. Clarithromycin solid lipid nanoparticles for topical ocular therapy: Optimization, evaluation, and in vivo studies. Pharmaceutics. 2021 Apr 9;13(4):523.
Lin S, Ge C, Wang D, Xie Q, Wu B, Wang J, Nan K, Zheng Q, Chen W. Overcoming the anatomical and physiological barriers in topical eye surface medication using a peptide-decorated polymeric micelle. ACS applied materials & interfaces. 2019 Oct 3;11(43):39603-12.
Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, Hadji H, Mitra R, Pal D, Mitra AK. A comprehensive insight on ocular pharmacokinetics. Drug delivery and translational research. 2016 Dec;6:735-54.
Souto EB, Dias-Ferreira J, López-Machado A, Ettcheto M, Cano A, Camins Espuny A, Espina M, Garcia ML, Sánchez-López E. Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents. Pharmaceutics. 2019 Sep 6;11(9):460.
Murthy KR, Goel R, Subbannayya Y, Jacob HK, Murthy PR, Manda SS, Patil AH, Sharma R, Sahasrabuddhe NA, Parashar A, Nair BG. Proteomic analysis of human vitreous humor. Clinical proteomics. 2014 Dec;11(1):1-1.
Del Amo EM, Rimpelä AK, Heikkinen E, Kari OK, Ramsay E, Lajunen T, Schmitt M, Pelkonen L, Bhattacharya M, Richardson D, Subrizi A. Pharmacokinetic aspects of retinal drug delivery. Progress in retinal and eye research. 2017 Mar 1;57:134-85.
Coca-Prados M. The blood-aqueous barrier in health and disease. Journal of Glaucoma. 2014 Oct 1;23:S36-8.
Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. European journal of ophthalmology. 2011 Nov;21(6_suppl):3-9.
Kreuter J. Colloidal drug delivery systems. CRC Press; 2014 Jul 22.
Batra M, Gupta S, Nair AB, Dhanawat M, Sandal S, Morsy MA. Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension. European Journal of Ophthalmology. 2021 Sep;31(5):2237-44.
Wang L, Zhou MB, Zhang H. The emerging role of topical ocular drugs to target the posterior eye. Ophthalmology and Therapy. 2021 Sep;10:465-94.
Anroop B, Ghosh B, Parcha V, Kumar A, Khanam J. Synthesis and comparative skin permeability of atenolol and propranolol esters. Journal of Drug Delivery Science and Technology. 2005 Jan 1;15(2):187-90.
Thareja A, Hughes H, Alvarez-Lorenzo C, Hakkarainen JJ, Ahmed Z. Penetration enhancers for topical drug delivery to the ocular posterior segment—a systematic review. Pharmaceutics. 2021 Feb 18;13(2):276.
Chen P, Chen H, Zang X, Chen M, Jiang H, Han S, Wu X. Expression of efflux transporters in human ocular tissues. Drug Metabolism and Disposition. 2013 Nov 1;41(11):1934-48.
Lee J, Pelis RM. Drug transport by the blood–aqueous humor barrier of the eye. Drug Metabolism and Disposition. 2016 Oct 1;44(10):1675-81.
Kraft ME, Glaeser H, Mandery K, König J, Auge D, Fromm MF, Schlötzer-Schrehardt U, Welge-Lüssen U, Kruse FE, Zolk O. The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Investigative ophthalmology & visual science. 2010 May 1;51(5):2504-11.
Gupta B, Mishra V, Gharat S, Momin M, Omri A. Cellulosic polymers for enhancing drug bioavailability in ocular drug delivery systems. Pharmaceuticals. 2021 Nov 22;14(11):1201.
Braga-Mele R, Chang DF, Henderson BA, Mamalis N, Talley-Rostov A, Vasavada A, ASCRS Clinical Cataract Committee. Intracameral antibiotics: safety, efficacy, and preparation. Journal of Cataract & Refractive Surgery. 2014 Dec 1;40(12):2134-42.
Varela-Fernández R, Díaz-Tomé V, Luaces-Rodríguez A, Conde-Penedo A, García-Otero X, Luzardo-Álvarez A, Fernández-Ferreiro A, Otero-Espinar FJ. Drug delivery to the posterior segment of the eye: Biopharmaceutic and pharmacokinetic considerations. Pharmaceutics. 2020 Mar 16;12(3):269.
Solinís MÁ, del Pozo-Rodríguez A, Apaolaza PS, Rodríguez-Gascón A. Treatment of ocular disorders by gene therapy. European Journal of Pharmaceutics and Biopharmaceutics. 2015 Sep 1;95:331-42.
Peng Y, Tang L, Zhou Y. Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases. Ophthalmic research. 2017 Sep 1;58(4):217-26.
Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG. Drug delivery to the posterior segment of the eye. Drug discovery today. 2011 Mar 1;16(5-6):270-7.
Qamar Z, Qizilbash FF, Iqubal MK, Ali A, Narang JK, Ali J, Baboota S. Nano-based drug delivery system: recent strategies for the treatment of ocular disease and future perspective. Recent Patents on Drug Delivery & Formulation. 2019 Dec 1;13(4):246-54.
Kesavan K, Mohan P, Gautam N, Sheffield VC. Topical Ocular Delivery of Nanocarriers: A Feasible Choice for Glaucoma Management. Current pharmaceutical design. 2020 Nov 1;26(42):5518-32.
Nair AB, Shah J, Jacob S, Al-Dhubiab BE, Sreeharsha N, Morsy MA, Gupta S, Attimarad M, Shinu P, Venugopala KN. Experimental design, formulation, and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. PloS one. 2021 Mar 19;16(3):e0248857.
Jacob S, Nair AB, Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomaterials research. 2020 Dec;24:1-6.
Jacob S, Nair AB, Shah J, Sreeharsha N, Gupta S, Shinu P. Emerging role of hydrogels in drug delivery systems, tissue engineering and wound management. Pharmaceutics. 2021 Mar 8;13(3):357.
Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles, and their targeted delivery applications. Molecules. 2020 May 8;25(9):2193.
Ako-Adounvo AM, C Nagarwal R, Oliveira L, HS Boddu S, S Wang X, Dey S, K Karla P. Recent patents on ophthalmic nanoformulations and therapeutic implications. Recent patents on drug delivery & formulation. 2014 Dec 1;8(3):193-201.
Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, Liu J, Gan Y. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug discovery today. 2013 Mar 1;18(5-6):290-7.
Almeida H, Amaral MH, Lobão P, Silva AC, Loboa JM. Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical formulations: present and future considerations. Journal of Pharmacy & Pharmaceutical Sciences. 2014 Jul 16;17(3):278-93.
Morrison PW, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Therapeutic delivery. 2014 Dec;5(12):1297-315.
Kamboj S, Bala S, Nair AB. Solid lipid nanoparticles: an effective lipid-based technology for poorly water soluble drugs. Int J Pharm Sci Rev Res. 2010 Nov;5(2):78-90.
De Oliveira IF, Barbosa EJ, Peters MC, Henostroza MA, Yukuyama MN, dos Santos Neto E, Löbenberg R, Bou-Chacra N. Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers. International Journal of Pharmaceutics. 2020 Nov 15;589:119831.
Shah J, Nair AB, Jacob S, Patel RK, Shah H, Shehata TM, Morsy MA. Nanoemulsion based vehicle for effective ocular delivery of moxifloxacin using experimental design and pharmacokinetic study in rabbits. Pharmaceutics. 2019 May 11;11(5):230.
López-Cano JJ, González-Cela-Casamayor MA, Andrés-Guerrero V, Herrero-Vanrell R, Molina-Martínez IT. Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection. Expert opinion on drug delivery. 2021 Jul 3;18(7):819-47.
Wadhwa J, Nair A, Kumria R. Self-emulsifying therapeutic system: a potential approach for delivery of lipophilic drugs. Brazilian Journal of Pharmaceutical Sciences. 2011;47:447-65.
Peters RP, Kestelyn PG, Zierhut M, Kempen JH. The changing global epidemic of HIV and ocular disease. Ocular Immunology and Inflammation. 2020 Oct 2;28(7):1007-14.
Duong VA, Nguyen TT, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules. 2020 Oct 18;25(20):4781.
Akrawi SH, Gorain B, Nair AB, Choudhury H, Pandey M, Shah JN, Venugopala KN. Development and optimization of naringenin-loaded chitosan-coated nanoemulsion for topical therapy in wound healing. Pharmaceutics. 2020 Sep;12(9):893
Battaglia LS, D’Addino I, Peira E, Trotta M, Gallarate M. Solid lipid nanoparticles prepared by coacervation method as vehicles for ocular cyclosporine. Journal of drug delivery science and technology. 2012;22:125-30.
Yadav M, Schiavone N, Guzman-Aranguez A, Giansanti F, Papucci L, Perez de Lara MJ, Singh M, Kaur IP. Atorvastatin-loaded solid lipid nanoparticles as eye drops: Proposed treatment option for age-related macular degeneration (AMD). Drug Delivery and Translational Research. 2020 Aug;10:919-44.
Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K, Rosenholm JM. Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. Pharmaceutics. 2018 Oct 18;10(4):191.
Wang, N., Cheng, X., Li, N., Wang, H. and Chen, H., 2019. Nanocarriers and their loading strategies. Advanced healthcare materials, 8(6), p.1801002.
Son, G.H., Lee, B.J. and Cho, C.W., 2017. Mechanisms of drug release from advanced drug formulations such as polymeric-based drug-delivery systems and lipid nanoparticles. Journal of Pharmaceutical Investigation, 47, pp.287-296.
Rajpoot K. Solid lipid nanoparticles: a promising nanomaterial in drug delivery. Current pharmaceutical design. 2019 Oct 1;25(37):3943-59.
Del Pozo-Rodríguez A, Delgado D, Gascón AR, Solinís MÁ. Lipid nanoparticles as drug/gene delivery systems to the retina. Journal of Ocular Pharmacology and Therapeutics. 2013 Mar 1;29(2):173-88.
Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, Kumar NS, Vekariya RL. A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC advances. 2020;10(45):26777-91.
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Advanced pharmaceutical bulletin. 2015 Sep;5(3):305.
Adhikari P, Pal P, Das AK, Ray S, Bhattacharjee A, Mazumder B. Nano lipid-drug conjugate: An integrated review. International journal of pharmaceutics. 2017 Aug 30;529(1-2):629-41.
Katouzian, I., Esfanjani, A.F., Jafari, S.M. and Akhavan, S., 2017. Formulation and application of a new generation of lipid nano-carriers for the food bioactive ingredients. Trends in Food Science & Technology, 68, pp.14-25.
Carbone, C., Leonardi, A., Cupri, S., Puglisi, G. and Pignatello, R., 2014. Pharmaceutical and biomedical applications of lipid-based nanocarriers. Pharmaceutical patent analyst, 3(2), pp.199-215.
Sala, M., Diab, R., Elaissari, A. and Fessi, H., 2018. Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications. Inter-national journal of pharmaceutics, 535(1-2), pp.1-17.
Lim, S.B., Banerjee, A. and Önyüksel, H., 2012. Improvement of drug safety by the use of lipid-based nanocarriers. Journal of controlled release, 163(1), pp.34-45.
Dri, D.A., Rinaldi, F., Carafa, M. and Marianecci, C., 2023. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes. Drug Delivery and Translational Research, 13(3), pp.757-769.
Subin, T.S., Vijayan, V. and Kumar, K.J.R., 2017. Updated regulatory considerations for nano-medicines. Pharmaceutical Nanotechnology, 5(3), pp.180-191.
